Lethal Prostate Cancer Treatment may Benefit from Combination Immunotherapy: Study

A genetic subset of prostate cancer may benefit from the use of combination checkpoint immunotherapy.

New study reported the effect of combination immunotherapy using both ipilimumab and nivolumab in prostate cancer patients.

Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) targeted AR-V7+ prostate cancer with a combination of two checkpoint blockers, ipilimumab and nivolumab, in 15 patients with this aggressive variant, first discovered at Johns Hopkins in 2014.

Brachytherapy for Prostate Cancer - Doses, Side Effects, Precautions
Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.

‘A genetic subset of prostate cancer may benefit from the use of combination checkpoint immunotherapy.’

This is the first clinical trial to target this specific form of prostate cancer, which can kill patients in only six to nine months and has inadequate treatment options.

The study was published by Oncotarget on June 19, 2018.

"This is the first prostate cancer study to be supported by the Bloomberg~Kimmel Institute for Cancer Immunotherapy since the institute was launched and provides the first evidence that immunotherapy can indeed benefit some patients with prostate cancer, a cancer type previously thought to be completely immunotherapy resistant," said Drew Pardoll, M.D., Ph.D., director of the BKI.

Drugs for Prostate Cancer - Treatment, Side Effects & Precautions
Prostate cancer is the main cause of cancer death in men. One of the treatment method includes prescribing chemotherapeutic or hormonal drugs. These are prescribed depending on the type and stage of cancer.

Patients on the trial received treatment by IV infusion consisting of 3 milligrams per kilogram of nivolumab plus 1 milligram per kilogram of ipilimumab every three weeks for four doses, followed by a maintenance regimen of 3 milligrams per kilogram of nivolumab alone every two weeks thereafter. The patients were enrolled between December 2016 and October 2017.

The data showed two out of the 15 men (13 percent) experienced a decrease in the level of prostate-specific antigen (PSA) of at least 50 percent. More encouragingly, one-quarter of patients achieved an objective response, meaning that their tumors shrank partially or completely with combination immunotherapy. These responses were typically lasted at least nine months. At least two of the patients remain alive for more than 18 months, which is much longer than expected for men with AR-V7+ prostate cancer.

Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!

Six of 15 patients (40 percent) had a genetic subtype of prostate cancer that harbored somatic and/or germline mutations in one DNA-repair genes involved in the BRCA pathway, first shown to predispose women to breast and ovarian cancer. In these six men, gene mutations of BRCA2, ATM, and ERCC4 were individually detected in those patients.

"Remarkably, all of the benefit from ipilimumab plus nivolumab appeared to occur in patients who had one of these gene mutations, particularly in two men with BRCA2 mutations," said Emmanuel Antonarakis, M.B.B.Ch., senior author of the study.

Benign Prostatic Hyperplasia Assessment | Prostate Self Assessment Calculator
Benign Prostatic Hyperplasia Assessment or Prostate Self Assessment Calculator assesses the symptoms of enlarged prostate gland and gives an early warning for benign prostatic hyperplasia.

"This finding is important, because BRCA2 is not a gene that was previously thought to sensitize patients to immune checkpoint inhibitors and, if true, will have profound implications for other diseases, such as breast and ovarian cancers where these genes are frequently mutated," said Antonarakis. "In the setting of prostate cancer, about 20-25 percent of patients have mutations in BRCA2 and related genes, which are involved in a DNA-repair process called homologous recombination. This study suggests that these gene mutations may be even more common in men with the AR-V7+ type of prostate cancer."

While prostate cancer is generally regarded as a low-mutation-burden tumor and immune-checkpoint blockade has resulted in only rare clinical regressions when used as a monotherapy, the data suggested AR-V7+ prostate cancers may be associated with a greater number of DNA-repair gene mutations and a higher mutation load and could be further exploited by using combination immunotherapy.

"If these findings are confirmed, this could offer some hope to these patients with AR-V7+ disease who have few, if any, good treatment options," said Antonarakis.

The study showed the combination of nivolumab plus ipilimumab demonstrated acceptable safety and tolerability in men with AR-V7+ advanced prostate cancer. Based on the encouraging preliminary findings, Antonarakis said he will expand his study to involve a greater number of patients. The expanded study is open to enrollment and actively seeking new patients.

Source-Eurekalert